Evonik Launches CYROLITE® Protect 2 For Antimicrobial Medical Devices
Evonik Cyro introduces CYROLITE® Protect 2, an acrylic-based multipolymer compound developed for medical devices with antimicrobial agents, at MD&M West at the Anaheim Convention Center, February 11-14.
CYROLITE® Protect 2 offers lipid and alcohol resistance in addition to the antimicrobial benefits of the original CYROLITE® Protect. All CYROLITE® Protect products are specifically designed for FDA regulated Class I or Class II medical devices covered by 510(k) PMN submission.
“Lipid and alcohol contact can cause devices made from other plastics to fail and CYROLITE® Protect 2 has been designed to address this challenge,” said Peter Allread, General Manager of Performance Polymers/Molding Compounds at Evonik. “The product’s new properties are important because the innovative multipolymer compound allows healthcare workers to use lipid IV solutions or swab devices with alcohol without fear of Environmental Stress Cracking (ESC).”
CYROLITE Protect 2 has a transparent blue tint and offers superior resistance to lipids and alcohol as well as excellent ductility.
CYROLITE® Protect 2 provides antimicrobial capabilities against microorganisms such as Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa and Staphylococcus epidermidis as tested by the JIS Z 2801 protocol.
“Healthcare experts have been increasingly concerned with hospital acquired infections and the costs associated with them,” said Wade Schneider, Medical Market Segment Manager at Evonik. “CYROLITE® Protect 2 helps prevent hospital acquired infections by eliminating bacteria on disposable medical devices close to a patient’s wound.”
For additional information about Evonik in North America, please visit our website: www.evonik.com/north-america. Please visit us on Facebook at www.facebook.com/EvonikNorthAmerica. Follow us on Twitter at http://twitter.com/EvonikN_America.
Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2012 more than 33,000 employees generated sales of around €13.4 billion and an operating profit (adjusted EBITDA) of about €2.4 billion (excluding Real Estate in both cases).
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.